Non-invasive prenatal tests (NIPT) are widely used to screen for chromosomal abnormalities in fetus. With none of them yet been authorised or approved by the U.S Food and Drug Administration (FDA), it has been cautioned to patients and healthcare providers that screening alone is not enough to rule out a suspected genetic abnormality. Additional diagnostic tests are highly recommended to confirm for any chromosomal abnormalities in the fetus.
Devyser offers a range of diagnostic kits (CE-IVD) for the rapid diagnosis of pregnancies at increased risk of aneuploidy in chromosomes 13, 18, 21, X or Y. Utilising Quantitative Fluorescent PCR (QF-PCR), a fast and reliable process, it also allows the detection of maternal cell contamination (MCC) and mosaicism.
